FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:201-202 January 20, 2000 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by The Heart Outcomes Prevention Evaluation Study Investigators PubMed Citation

An important article in this issue of the Journal describes the results of the Heart Outcomes Prevention Evaluation (HOPE) study, which are likely to have important implications for the treatment of cardiovascular disease.¹ The findings indicate that ramipril, an angiotensin-converting–enzyme (ACE) inhibitor, substantially lowers the risk of death, heart attack, stroke, coronary revascularization, heart failure, and complications related to diabetes mellitus in a high-risk group of patients with preexisting vascular disease. The study was stopped early by the data and safety monitoring board because of the obvious benefit of ramipril. The results are remarkable both for the magnitude of the . . . [Full Text of this Article]

References

Related Letters:

Effect of Ramipril on Cardiovascular Events in High-Risk Patients
Weinsaft J. W., O'Rourke M. F., Nichols W. W., Sharma A. M., Pischon T., Engeli S., Gavras H., Yusuf S., Francis G. S.
Extract | Full Text  
N Engl J Med 2000; 343:64-66, Jul 6, 2000. Correspondence

This article has been cited by other articles:

• Paul-Labrador, M., Polk, D., Dwyer, J. H., Velasquez, I., Nidich, S., Rainforth, M., Schneider, R., Merz, C. N. B. (2006). Effects of a randomized controlled trial of transcendental meditation on components of the metabolic syndrome in subjects with coronary heart disease.. Arch Intern Med 166: 1218-1224 [Abstract] [Full Text]  
• Modesti, A., Bertolozzi, I., Gamberi, T., Marchetta, M., Lumachi, C., Coppo, M., Moroni, F., Toscano, T., Lucchese, G., Gensini, G. F., Modesti, P. A. (2005). Hyperglycemia Activates JAK2 Signaling Pathway in Human Failing Myocytes via Angiotensin II-Mediated Oxidative Stress. Diabetes 54: 394-401 [Abstract] [Full Text]  
• Lim, H. S., MacFadyen, R. J., Lip, G. Y. H. (2004). Diabetes Mellitus, the Renin-Angiotensin-Aldosterone System, and the Heart. Arch Intern Med 164: 1737-1748 [Abstract] [Full Text]  
• Houser, S. R., Margulies, K. B. (2003). Is Depressed Myocyte Contractility Centrally Involved in Heart Failure?. Circ. Res. 92: 350-358 [Abstract] [Full Text]  
• Lamy, A., Yusuf, S., Pogue, J., Gafni, A., on Behalf of the HOPE Investigators*, (2003). Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 107: 960-965 [Abstract] [Full Text]  
• Messerli, F. H., White, W. B., Staessen, J. A. (2002). If only cardiologists did properly measure blood pressure: Blood pressure recordings in daily practice and clinical trials. J Am Coll Cardiol 40: 2201-2203 [Abstract] [Full Text]  
• Goette, A., Lendeckel, U., Klein, H. U (2002). Signal transduction systems and atrial fibrillation. Cardiovasc Res 54: 247-258 [Abstract] [Full Text]  
• Vickers, C., Hales, P., Kaushik, V., Dick, L., Gavin, J., Tang, J., Godbout, K., Parsons, T., Baronas, E., Hsieh, F., Acton, S., Patane, M., Nichols, A., Tummino, P. (2002). Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase. J. Biol. Chem. 277: 14838-14843 [Abstract] [Full Text]  
• Gorelick, P. B. (2002). Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy: An Invited Review. Stroke 33: 862-875 [Abstract] [Full Text]  
• Prasad, A., Mincemoyer, R., Quyyumi, A. A. (2001). Anti-ischemic effects of angiotensin- converting enzyme inhibition in hypertension. J Am Coll Cardiol 38: 1116-1122 [Abstract] [Full Text]  
• Fiordaliso, F., Leri, A., Cesselli, D., Limana, F., Safai, B., Nadal-Ginard, B., Anversa, P., Kajstura, J. (2001). Hyperglycemia Activates p53 and p53-Regulated Genes Leading to Myocyte Cell Death. Diabetes 50: 2363-2375 [Abstract] [Full Text]  
• Givertz, M. M. (2001). Manipulation of the Renin-Angiotensin System. Circulation 104 : e14-e18 [Full Text]  
• Yacoub, M.H. (2001). A novel strategy to maximize the efficacy of left ventricular assist devices as a bridge to recovery. Eur Heart J 22: 534-540  
• O'Keefe, J. H., Wetzel, M., Moe, R. R., Brosnahan, K., Lavie, C. J. (2001). Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?. J Am Coll Cardiol 37: 1-8 [Abstract] [Full Text]  
• Port, S., Garfinkel, A., Boyle, N. (2000). There is a non-linear relationship between mortality and blood pressure. Eur Heart J 21: 1635-1638  
• Sibinga, N. E. S., Ware, J. A. (2000). A Pair of ACEs, for Openers?. Circ. Res. 87: 523-525 [Full Text]  
• Weinsaft, J. W., O'Rourke, M. F., Nichols, W. W., Sharma, A. M., Pischon, T., Engeli, S., Gavras, H., Yusuf, S., Francis, G. S. (2000). Effect of Ramipril on Cardiovascular Events in High-Risk Patients. NEJM 343: 64-66 [Full Text]  
• Fowler, P.B.S. (2000). The thyroid, blood flow and atheroma. QJM 93: 477-485 [Full Text]  
• Sleight, P. (2000). The HOPE Study (Heart Outcomes Prevention Evaluation). Journal of Renin-Angiotensin-Aldosterone System 1: 18-20